Merck Sharpe and Dohme versus Laporte

Lancet. 2004;364(9432):416. doi: 10.1016/S0140-6736(04)16761-5.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Arthritis, Rheumatoid / drug therapy
  • Cyclooxygenase Inhibitors / adverse effects
  • Drug Industry / legislation & jurisprudence*
  • Humans
  • Lactones / adverse effects*
  • Publishing / legislation & jurisprudence
  • Publishing / standards*
  • Randomized Controlled Trials as Topic / standards
  • Scientific Misconduct / legislation & jurisprudence*
  • Spain
  • Sulfones

Substances

  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib